Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AMYRIS : Amyris's First Commercial Production Facility Complete and Operational

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2011 | 02:05pm CEST

Amyris, Inc., (NASDAQ:AMRS), a renewable chemicals and fuels company, today announced the completion of the first industrial-scale facility for the production of Biofene?, Amyris's renewable farnesene. The production facility is located in Piracicaba, São Paulo, Brazil at a facility owned by Biomin do Brasil Nutri?ão Animal Ltda., a company focusing on animal nutrition. Amyris will operate the production facility and expects to begin Biofene production in May. To produce Biofene, Amyris feeds sugar cane syrup into three dedicated 200,000 liter fermentors containing Amyris proprietary yeast. The yeast digest the syrup feedstock and produce farnesene, which is then separated and purified. Biofene may then be sold directly into industrial applications or put through simple chemical finishing steps to form a broad range of renewable products including squalane, base oil and finished lubricants and diesel.

To achieve production at full industrial scale, Amyris has developed an integrated scale-up process which connects ongoing advances in Amyris research with industrial-scale production. By miniaturizing process conditions found in production-scale fermentors, Amyris has been able to translate yeast performance successfully from discovery to production. Amyris further controls scale-up by testing performance in its pilot plant in Emeryville, Calif., followed by vetting in a second pilot plant and a demonstration facility in Amyris's operations in Campinas, Brazil. Earlier this year, Amyris tested its yeast strains and process in several runs at 100,000 and 200,000 liter scale and generated results that were consistent with previous runs at smaller scale.

"The completion of our first Biofene production facility is a landmark not only for Amyris but also for the renewable products sector," said John Melo, CEO of Amyris. "With this milestone, we are demonstrating that engineered yeast may be used to produce high-value hydrocarbon molecules on a commercial scale. This achievement reinforces our goal of providing No Compromise® renewable alternatives to petroleum to transform the chemicals industry, extend the world's fuel supply and contribute to the betterment of our environment."

Amyris is scaling its production through contract agreements with manufacturers located in Brazil, Europe and the United States, and has five production agreements in place including contract agreements with Antibioticós S.A., Biomin, Paraíso Bioenergia S.A., Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC, and a joint venture with Usina São Martinho S.A., one of the largest sugar and ethanol producers in Brazil. Amyris has also established finishing capabilities with Glycotech, Inc.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a wholly owned subsidiary, has over 100 employees based in Campinas, Brazil and oversees Amyris's production and commercialization in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding commercial-scale production and commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on March 14, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Schwartz Communications
Merrill Freund or Alison Mickey, 415-817-2557
[email protected]


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
06/22 AMYRIS : US company plans regional Queensland biorefinery to make cosmetics from..
06/22 AMYRIS : Queensland move forward with planned biorefinery
06/21 AMYRIS, INC. : Other Events (form 8-K)
06/20 AMYRIS : Partners with Queensland on Biofutures Acceleration Program in Next Ste..
06/20 Amyris Partners with Queensland on Biofutures Acceleration Program in Next S..
06/19 AMYRIS INC : DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action L..
06/19 AMYRIS INC : FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds In..
06/16 AMYRIS INC : 3-DAY DEADLINE: Lundin Law PC Announces a Securities Class Action L..
06/16 AMYRIS INC : DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Amyr..
06/15 AMYRIS INC : AMRS The Law Offices of Vincent Wong Reminds Investors of a Class A..
More news
Sector news : Industrial Biotechnology Chemicals
06/01 JOHNSON MATTHEY : expects higher catalysts demand after profit rises
05/23DJWHAT'S NEWS : Business & Finance -- WSJ
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22 LafargeHolcim hires Sika boss as next CEO
05/22DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Industrial Biotechnology Chemicals
News from SeekingAlpha
05/19 Amyris (AMRS) Investor Presentation - Slideshow
05/15 Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript
05/15 Amyris misses by $0.04, misses on revenue
05/14 Notable earnings after Monday?s close
04/20 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia ..
Advertisement
Financials ($)
Sales 2017 121 M
EBIT 2017 -54,0 M
Net income 2017 -83,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0,53x
Capi. / Sales 2018 0,31x
Capitalization 63,8 M
More Financials
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Full-screen chart
Technical analysis trends AMYRIS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 15,0 $
Spread / Average Target 366%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Louis John Doerr Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%64
HENKEL10.82%57 915
ECOLAB INC.12.42%38 222
SIKA28.99%14 067
SYMRISE10.06%9 523
TRANSFAR ZHILIAN CO LT..--.--%7 368
More Results